❗️DISPAIR + D-FRS, a thread❗️
1/7
2284 patients undergoing left pancreatectomy at 9 different high-volume centers 🏥
497 developed POPF. How well did the D-FRS and the DISPAIR models predict POPF?
D-FRS: AUC = 0.62
DISPAIR: AUC = 0.62
Calibration⬇️
https://t.co/0L4iitbnQY
At European Surgical Association (ESA) meeting in Rome, @BonsdorffA presenting our work, GALL-PAL score for predicting pain alleviation after cholecystectomy for uncomplicated cholecystitis. Hope to have this fully out soon!
Compared with stapler closure, hand-sewn closure is associated with worse short-term outcomes, including increased postoperative pancreatic fistula incidence.
📑:https://t.co/qPDYcOxMlj
I just received the news that I have been awarded 1.25milEUR grant for the @SigridJuselius professorship! Deeply grateful for all the support from so many during my path! I need to sit down for a while…
New study from the DISPAIR consortium @BjsOpen!
Refined classification of postoperative pancreatic fistula after left pancreatectomy based on cumulative morbidity.
Open Access: https://t.co/WrnHwaFrhb
Great and inspiring talk by @sparrelid from @HpbKarolinska at Finnish Surgical Society’s Operative Days in Helsinki - Clear benefit of fellowships both for the fellow and the host - win-win! Congrats @KarolinskaUnsju for the huge work!
All good things come to an end! Hugely successful #NordicHPB meeting wrapped up!
Spectacular presentations on minimally & maximally invasive HPB, endoscopic methods, oncology, diagnostics and more!
Grateful to all presenters and participants for discussion!
Some highlights👇🧵
Assessment of D-FRS on external cohort in San Raffaele, Milan, Italy
AUC 0.49, discrimination and calibration poor.
👉 Shows nicely why external validation is so important!
Would love to see DISPAIR-FRS to be further validated externally!
https://t.co/tHshttMZ0O @spartelli
Another 💎 from DISPAIR consortium @SurgJournal: Does neoadjuvant therapy reduce complications after left pancreatectomy?
9 high-volume centers, propensity score matched
Pancreatic fistula: neoadjuvant 20% vs 24%, p=0.7
No diff in other complications.
https://t.co/1EV9bOZ9vB
From the DISPAIR consortium group presented by @BonsdorffA at @EAHPBA 2025 Dublin.
Extremely high morbidity heterogeneity within grade B pancreatic fistula (from ab to invasive treatment).
Should we update the postop pancreatic fistula classification?
Here’s a proposal (A-B-C)
🔵 Pancreas2000 is the young talent group of the @EurPancClub and is aimed at shaping the nextgen of pancreas experts
🙏 I feel very privileged to coordinate this program, our future is in good hands! 💙
Relationship between resection rate and survival in pancreatic cancer *at population-level* by @elockie18&al @BjsOpen
👉The more you resect the better survival for the whole population
👉Efforts to increase the resection rate
Commentary by @chiaro_del&al
Links👇
7/7
This was a huge team effort and I want to extend my heartfelt thanks to everyone from our 30 person collaboration participating! Special thanks of course to @villesallinen for guidance and mentorship🤝
@BJSurgery@BJSAcademy@me4_so@hpb_so
❗️DISPAIR + D-FRS, a thread❗️
1/7
2284 patients undergoing left pancreatectomy at 9 different high-volume centers 🏥
497 developed POPF. How well did the D-FRS and the DISPAIR models predict POPF?
D-FRS: AUC = 0.62
DISPAIR: AUC = 0.62
Calibration⬇️
https://t.co/0L4iitbnQY
6/7
Final model, the DISPAIR-FRS, can be accessed at https://t.co/d88P7kpzBC.
⚙️AUC = 0.72
⚙️Calibration slope = 0.93
⚙️Calibration intercept = -0.02
The user has an option to ”calibrate” predictions with institutional baseline risk for POPF.
Predicting risk for pancreatic fistula after left pancreatectomy:
2 risk scores were assessed in international cohort of 2284 patients from 🇫🇮🇬🇧🇸🇪🇫🇷🇳🇴🇨🇦🇩🇰
DISPAIR and D-FRS performed poorly
👉 We combined and validated new DISPAIR-FRS score with better performance
Links 👇